Summary The metabolism of serotonin was studied in cancer patients of their first day of their first course of chemotherapeutic drugs either with strongly or moderately emetogenic regimens. It was observed that strongly emetogenic treatments induce greater increases in serotonin release than moderately emetogenic regimens. High-dose cisplatinum (75 ± 5 or 83.8 ± 5 mg m-2) produced a marked increase in the plasma levels and in the urinary excretion of 5-hydroxyindole acetic acid (5-HIAA). Neither platelet nor plasma (platelet-free plasma) serotonin were significantly modified by high-dose cisplatinum. Dacarbazine (283 ± 22mg m-2), another strongly emetogenic agent, induced acute nausea and emesis paralleled by marked increases in the urinary excretion of 5-HIAA. Both for high-dose cisplatinum and dacarbazine, the increases in serotonin metabolism occurred with a similar time-course than those of vomiting, and lasted for a period of 4 to 8 h. Low-dose cisplatinum (30.8 ± 3 mg m-2) as well as cyclophosphamide-based chemotherapies (520±30mg m-2) produced very small increases in the urinary excretion of 5-HIAA. Platelet and plasma serotonin levels failed to increase in cyclophosphamide-treated patients. Octreotide, a long-acting somatostatin analog, did not inhibit the increase in urinary 5-HIAA and the nausea and vomiting produced by high-dose cisplatinum. These results suggest that for treatments that induce marked increases in serotonin release such as high-dose cisplatinum or dacarbazine: (a) the amount and time course of serotonin release induced by chemotherapeutic drugs determines the severity, time of onset and pattern of emesis observed; (b) platelet serotonin play no role in chemotherapy-induced emesis; (c) strongly emetogenic regimens release serotonin from enterochromaffin cells; and (d) intestinal release of serotonin is the consequence of the damage induced by the chemotherapeutic drugs on the gut mucosa.
Nausea and vomiting are serious and frequent complications of chemotherapeutic drugs (Fetting et al., 1982; Lazlo, 1983; Martin-Jimenez & Diaz-Rubio, 1985; Gralla et al., 1987) . In addition to marked discomfort, nausea and vomiting affect patient compliance with subsequent chemotherapy courses and have been reported to produce physical lesions and fluid and electrolyte disturbances (Enck, 1977; Lazlo & Lucas, 1981; Martin-Jimenez et al., 1988) . In the absence of effective antiemetic treatment, all patients receiving dacarbazine or cisplatinum and 60% or more of patients treated with cyclophosphamide-containing regimens experience emesis of moderate to intense severity (Fetting et al., 1982; MartinJimenez & Diaz-Rubio, 1985; Gralla et al., 1981) . It has not been until recently that some light has been shed on the mechanisms of vomiting associated to chemotherapeutic drugs. Serotonin seems to play an important role in the nausea and vomiting induced by chemotherapeutic agents. In fact, depletion of tissue serotonin has been shown to abolish cisplatinum-induced vomiting in laboratory animals (Barnes et al., 1987) and selective antagonists of serotonin type-3 receptors (5-HT3) reduced the emetic response associated with chemotherapy, both in animals and human cancer patients (Leibundgut & Lancranjan, 1987; Cubeddu et al., 1990a,b; Marty et al., 1990) . Further, an increase in the urinary excretion of 5-hydroxyindole-acetic acid (5-HIAA), the main metabolite of serotonin, was reported in cancer patients receiving high doses of cisplatinum . Therefore, it has been proposed that serotonin acting on 5-HT3 receptors mediates at least part of the nausea and vomiting induced by chemotherapeutic drugs (Miner & Sanger, 1986; Costall et al., 1986; Stables et al., 1987) .
The present study was conducted to investigate further, in cancer patients, the mechanisms by which chemotherapeutic drugs elicits nausea and vomiting. The changes in serotonin levels and metabolism were evaluated on the first day of the first cycle of treatment with two strongly emetogenic regimens: high-dose cisplatinum and dacarbazine-based chemotherapies, and with two moderately emetogenic treatments: low-dose cisplatinum and cyclophosphamide-based chemotherapies. Specifically, we determined: (a) if serotonin is released only by high-dose cisplatinum or could also be released by other commonly employed chemotherapeutic agents; (b) if there is a relationship between the amount of serotonin released and the magnitude of the emetic response to chemotherapeutic drugs, and (c) if there is a temporal relationship between the release of serotonin and the nausea and vomiting. In addition, the site from which serotonin is released was investigated by measuring the plasma-free and platelet concentrations of serotonin and the plasma-free and urinary excretion of 5-HIAA following chemotherapy. Finally, the mechanism by which chemotherapeutic drugs induce serotonin release was assessed by studying the effects of octreotide on serotonin release and metabolism, in cancer patients receiving high-dose cisplatinum. Octreotide, a long-acting somatostatin analog, is a well known inhibitor of hormonal secretion and inhibits the release of serotonin from neoplasms of enterochromaffin cells (Reichlin et al., 1985; Kvols, 1988; Katz & Erstad, 1989 Chemotherapy and antiemetic treatment Four types of regimens were studied: high dose cisplatinum (> 50 mgm-2), low dose cisplatinum (< 40 mgm-2), cyclophosphamide-based (> 500 mgm-2) and dacarbazine-(250-300 mg m-2) based treatments. Patients received only one of the strongly emetic regimens. Namely, if they received highdose cisplatinum they did not receive dacarbazine and vice versa. In addition, the cyclophosphamide-based regimens did not contain cisplatin or dacarbazine. However, the cisplatinum or dacarbazine-based chemotherapies could include cyclophosphamide. Cisplatinum, cyclophosphamide or dacarbazine were dissolved in 500 ml of 5% dextrose in 0.45% sodium chloride and administered at a 60-min intravenous infusion. The primary agent was followed by administration of other chemotherapeutic drugs as required for treatment 
Analytical methods

Plasma and platelet serotonin
In patients receiving high-dose cisplatinum or cyclophosphamide, blood samples were obtained at 30 intervals starting 1 h prior to the chemotherapeutic drug for 4 h; subsequently, samples were obtained every 2 h for 6 additional hours. The samples were drawn by venipuncture or through an intravenous line, with plastic syringes before and after administration of the most emetogenic chemotherapeutic drug. Blood was immediately placed in chilled plastic tubes containing Na2EDTA 1 mg ml -and sodium metabisulfite 2 mg ml1'. After gentle mixing, blood was centrifuged at 800 g for O min in a Sorvall Centrifuge (R5) at 4°C. The pellet was discarded and the supernatant contained the platelet-rich plasma. A 20 t l I aliquot of the supernatant was diluted in 20 ml of Isopton-2 and the platelet count performed using a previously calibrated Coulter Thrombo-Counter. A 2 ml sample of the platelet-rich plasma was centrifuged at 7,000g for O min, after additional of dithiotreitol (final concentration 10 1M). The supernatant containing the platelet-free plasma was treated with perchloric acid (final concentration 0.4 M), mixed and then centrifuged at 10,000 g for 5 min to precipitate the proteins. The supernatant containing the free serotonin and 5-HIAA was stored at -40°C until assay (within 1-2 days). The platelet pellet (pellet from 7,000g centrifugation) was suspended in perchloric acid 0.1 M homogenised and centrifuged at 10,000 g for 5 min. This procedure was repeated twice. The supernatants were combined, stored at -440C until assayed for platelet serotonin.
Total serotonin was calculated as follows: platelet serotonin + free serotonin in plasma. Both, platelet and free serotonin were expressed per ml of plasma. The total plasma serotonin was obtained from the calculated concentration of serotonin in plasma times the plasma volume (average plasma volume for females and males is 40 and 39 ml per In this first study, a detailed analysis of the effects of highdose cisplatinum on serotonin metabolism was undertaken.
Blood and urine samples for assay were obtained from 16 consecutive cancer hospital inpatients (6M/1OF; mean age 54 ± 6 years) scheduled to receive their first course of chemotherapeutic drugs with high-dose cisplatinum (mean dose: 75± Smgm2).
In the blood samples collected prior to the chemotherapeutic drugs, nearly 98% of blood serotonin (212 ± 27 ng ml-' plasma) was found in the platelet-rich plasma fraction; whereas, free serotonin (present in platelet-free plasma) averaged 3.2 ± 0.3 nanograms ml-' plasma. The content of serotonin per platelet averaged 0.33 ng/platelet. The total amount of serotonin circulating in blood (platelets + free) was estimated between 0.8 and 1.4 mg. No significant changes in the content of serotonin per platelet, the number of platelets or the concentration of serotonin per ml of plasma were observed in the samples collected over the 10 h period following cisplatinum administration (Figure 1 ). Free serotonin levels showed a tendency to increase from 3 to 7 h after cisplatinum; however, the changes did not reach statistical significance (Figure 1 ). On the other hand, there were larger and sustained increases above baseline in the levels of 5-HIAA in plasma and urine following high-dose cisplatinum (Figures 1 and 2) . At 3 and 5 h after cisplatinum 5-HIAA concentrations doubled those at baseline. Subsequently, the plasma 5-HIAA levels declined, returning to the baseline levels 9 h after cisplatinum administration. The changes in the urinary excretion of 5-HIAA paralleled those of plasma 5-HIAA (Figures 1 and 2 ). Increases in urinary 5-HIAA were observed for the actual rate of excretion (micrograms of 5-HIAA/2 h) (data not shown), as well as after correcting by urinary creatinine (nanograms 5-HIAA/microgram creatinine) (Figure 2 ). The total increase above baseline levels of 5-HIAA for the 2 to 8 h after cisplatinum, averaged 1.86 mg. The urinary excretion of 5-HIAA measured in a control group of healthy volunteers (3M/3F) showed no significant increases in 5-HIAA, with a 50% decrease in the evening-night (8-24 h) urine sample.
In three patients, the vomiting fluid was assayed for serotonin; however, no serotonin was detected.
Relationship between the dose of cisplatinum and the increases in urinary excretion of S-HIAA In a second study, a total of 12 consecutive chemotherapynaive patients received either > 50 mg m-2 (high dose; n = 6; SM/IF; mean age: 54.3 ± 6 years) or <40 mg m 2 (low-dose cisplatinum; n = 6; 4M/2F; mean age: 51.1 ± 6 years) according to the type and stage of their tumours. The average dose of cisplatinum for the high-dose group was 83.8 ± 5 mg m-2 and for the low-dose group was 30.8 ± 3 mg m 2 (P < 0.001). As shown in the first study, high-dose cisplatinum produced large increases in the urinary excretion of 5-HIAA (Figure 3) . The sample collected 4-6 h after high-dose cisplatinum showed 5-HIAA levels that were 3 fold higher than those at Time (h) Figure 3 Comparative effects of chemotherapy with low-dose and high-dose cisplatinum on the urinary excretion of 5-HIAA, in cancer patients. Chemotherapy-naive cancer patients received treatments based on low-dose (< 40 mg m') or high-dose cisplatinum ( > 50 mg m-2). Cisplatinum was administered intravenously in 1 h. Urine samples were obtained at 2 h intervals prior to and after cisplatinum administration (time zero). Time zero is the time in initiation of cisplatinum infusion. Different from baseline at *P< 0.05; **P < .0l.
baseline. There were no significant changes in the urinary excretion of 5-HIAA in the low-dose cisplatinum group; however, 6 to 10 h after the chemotherapeutic drugs the 5-HIAA excretion was 60 to 100% higher than at baseline (Figure 3) . The lack of a significant increase in 5-HIAA excretion may be explained by the fact that only half of the low-dose cisplatinum patients had an increase in 5-HIAA excretion; whereas, all patients in the high dose group showed increases in 5-HIAA excretion above baseline. (Figure 1 ). Compared to high-dose cisplatinum and dacarbazine (see below), cyclophosphamide produced a small increase (30% above baseline) in the urinary excretion of 5-HIAA during the first 8 h following its administration (Figure 2) . However, the levels of 5-HIAA persisted elevated in the 8 to 24h urinar sample following treatment with cyclophosphamide; whereas in the control group, the 5-HIAA/creatinine ratio decreased from 5.8 ± 1 in the 6-8 h sample to 2.4 ± 0.3 in the 8-24h sample. A similar magnitude of increase in the 8-24 h excretion of 5-HIAA was observed in the high-dose cisplatinum, dacarbazine and cyclophosphamide-treated patients (P>0.1) (Figure 2 ). The median time to emesis for cyclophosphamide-treated patients was of 9.4 h. The effects of 250-300mgm-2 dacarbazine (mean dose: 283 ± 22 mg m-2) on 5-HIAA excretion are shown on Figure  2 . A total of five cancer patients (3F/2M; age: 39.6 ± 7 years) received treatment with dacarbazine in combination with any of the following: doxorubicin, iphosphamide or cyclophosphamide. Dacarbazine induced a marked and rapid increase in the urinary excretory rate of 5-HIAA. This increase was similar to that observed with cisplatinum, and paralleled the rapid onset of nausea and vomiting observed in the dacarbazine-treated patients. Despite antiemetic protection (metoclopramide + diphenhydramine), the time to the onset of emesis was 2.5 ± 0.8 h.
Effects of a somatostatin analog in high-dose cisplatinum-induced emesis and on 5-HIAA excretion This experiment was undertaken with purpose of exploring the mechanism of chemotherapy-induced serotonin release. Somatostatin is a well known inhibitor of hormonal release (Katz & Erstad, 1989) . The long-acting somatostatin analog, octreotide Sandostatin) , has been shown to alleviate symptoms, to reduce the release of serotonin and the levels of 5-HIAA in patients harboring carcinoid tumours (see Kvols, 1988 for review). The possibility that cisplatinum induced serotonin release and nausea and vomiting, could be prevented by pretreatment with octreotide was investigated, in cancer patients receiving high-dose cisplatinum. The effects of two different regimens of octreotide were employed: (a) 250 micrograms sc 1 h before and 1 h after cisplatinum, or (b) at 250 micrograms sc every 8 h the day before and 500 micrograms sc 1 h before and 1 h after cisplatinum. These treatments failed to prevent the emetic response to cisplatinum. In addition, similar increase in the excretion of urinary 5-HIAA were observed in octreotide-treated patients than in control patients receiving high-dose cisplatinum (Table I) .
Discussion
In the present study we evaluated the changes in serotonin and in serotonin metabolism produced by cancer chemotherapeutic drugs with the purpose of understanding the mechanisms by which these agents induce nausea and vomiting. The serotonin metabolism and the vomiting could be due to the primary agent, the contribution of other agents cannot be ruled out. However, in our design, the emetogenic activity of the associated drugs was less than that of the primary agent.
The observation that depletion of serotonin prevents cisplatinum-induced vomiting (Barnes et al., 1987) , and that antagonists of serotonin-type 3 receptors are effective against radiation-and chemotherapy-induced emesis (Miner & Sanger, 1986; Costall et al., 1986; Smith et al., 1986; Stables et al., 1987; Fozard, 1987; Andrews et al., 1988; Hawthorn et al., 1988; , suggests that serotonin plays a critical role in the emetic response to these treatments. The present study provides further evident of the role of serotonin in chemotherapy-induced nausea and vomiting. First, two strongly emetogenic cytotoxic drugs, high-dose cisplatinum and dacarbazine, induced marked increases in the metabolism of serotonin in a time course that paralleled the onset of nausea and vomiting. Both high-dose cisplatinum and dacarbazine induce an early (2-3 h after chemotherapy) and intense emetic response of 4 to 6 h duration (Martin-Jimenez y Diaz-Rubio, 1985; Gralla et al., 1981; ; present study). For high-dose cisplatinum and for dacarbazine, the comparable time courses for emesis and for the increase in serotonin metabolism suggests a cause-effect relationship between serotonin and the emetic response. Second, two chemotherapeutic drugs with mild to moderate emetic activity, cyclophosphamide and low-dose cisplatinum, produced smaller and less consistent increases in serotonin metabolism than the strongly emetogenic cytotoxics; therefore, a temporal relationship between the emetic response and the urinary excretion of 5-HIAA could not be determined for these two treatments. Contrary to cisplatinum and dacarbazine, cyclophosphamide does not produce early emesis (Fetting et al., 1982; Cubeddu et al., 1990b) , nor does it produce an early increase in 5-HIAA (present study). The results of this study suggest that the amount of serotonin released and the time course of the release determines the severity, the time of onset and the pattern of emesis induced by a specific chemotherapeutic drug. If a cytotoxic drug induces a large release of serotonin within a short period of time, an intense period of vomiting would be expected for this drug, associated to large increases in urinary excretion rate of 5-HIAA. However, if lower amounts of serotonin are released or even if the total amount of serotonin released is similar to that produced by high-dose cisplatinum, but the release occurs over a long period of time (i.e., 24 h), only mild to moderate vomiting spread out over the time of serotonin release would develop. In addition, significant increases above baseline in urinary 5-HIAA excretion may not be observed since the amount of serotonin released will be diluted over many hours.
Information about the source of serotonin released by chemotherapeutic drugs can be obtained from data on the normal distribution of serotonin in the body. In humans, nearly 80% of the serotonin is in the gastrointestinal tract (6-9 mg), 95% of which is within enterochromaffin, as well as in other enteroendocrine cells. The rest of the body serotonin is divided between platelets (1-2mg), and other tissues, including the CNS (1 mg) (Feldberg & Toh, 1953; Ersparmer, 1954; (Ersparmer & Testini, 1959; Bertaccini, 1960) . Therefore, an increase in urinary 5-HIAA excretion (in the absence of carcinoid tumoral cells) should reflect increases in turnover (increase synthesis and/or release) of gastrointestinal serotonin. Interestingly, in ferrets, cisplatinum increases the gastrointestinal turnover of serotonin (Gunning et al., 1987 Kvols, 1988) . In favour of a local, intestinal site of action for serotonin, is the observation that visceral denervation of the ferret, prevents cisplatinum-induced vomiting in this animal (Hawthorn et al., 1988) . Presently, the mechanism by which chemotherapeutic agents induce the release of serotonin is unknown. The presence of receptors on enterochromaffin and in enteroendocrine cells for each of the cytotoxics is unlikely, rather a mechanism related to their cytotoxicity is more plausible. The drugs with strongest emetic activity act as aklylating agents, inhibit DNA biosynthesis and kill cells in all stages of the cell cycle. Rapid cell killing may release substances from dying cells that induce serotonin release from enteric serotonincontaining cells, the cytotoxics may have a specific direct damaging effect on the serotonin cells and/or produce severe mucosal damage and an unspecific damage of the serotonincontaining cells leading to serotonin release. If the release occurs through a normal secretory process, it would be sensitive to somatostatin, a well known inhibitor of hormonal secretion (Katz & Erstad, 1989; Reichlin, 1985) and of serotonin release from carcinoid tumours, which are neoplasms of enterochromaffin cells (Kvols, 1988) . Octreotide, a stable long-acting analog of the peptide hormone somatostatin, reduces clinical symptoms, inhibits serotonin release and decreases urinary levels of 5-HIAA in carcinoid patients (see Kvols, 1988 for review). However, with the two treatment schedules employed the somatostatin analog failed to prevent both the emetic response as well as the increases in 5-HIAA induced by high-dose cisplatinum in cancer patients (present study). These results suggest that cisplatinum in high doses induces serotonin release by a mechanism different of the normal secretory hormonal release, and of that observed in tumoral enterochromaffin cells. Studies in experimental animals revealed a severe mucosal damage of the ileum and jejunum after high-dose cisplatinum, and that the extent of the damage was related to the severity of emesis (Gunning et al., 1987) . Consequently, although the precise mechanism of cytotoxic-induced gastrointestinal serotonin release is unclear, it seems to be through a direct or indirect lesion of the enterochromaffin cells.
In summary, the serotonin hypothesis could be stated as follows: 'chemotherapeutic drugs and radiotherapy induces the release of serotonin from enterochromaffin and/or other enteroendocrine cells perhaps by damage of the gut mucosa, the released serotonin would activate 5-HT3 receptors on visceral afferent fibres increasing afferent input to the brain, stimulating the chemoreceptor trigger zone and/or vomiting centre with the consequent production of nausea and emesis.
The serotonin released would be metabolised within the intestine and/or on its passage through the liver, leading to increases both in plasma and urine of its main metabolite, (Smith et al., 1988) and the central administration of 5-HT3 antagonists prevents vomiting induced by cisplatinum (Higgins et al., 1989) . The largest concentration of 5-HT3 receptors is present in the brain medulla in the nucleus tractus solitarious and area postrema regions, where the chemoreceptor trigger zone is located and where the vagal afferents enter the brain . On this line, we may add that patients receiving low doses of cisplatinum or cyclphosphamide-based treatments showed either small or no increases in urinary 5-HIAA excretion, nevertheless they experienced mild to moderate emesis, and their emesis was controlled by 5-HT3 antagonists (Cubeddu et al., 1990b) . One possibility is that measurements of urinary 5-HIAA may not be sensitive enough to detect small increases in serotonin release induced by cytotoxics with mild to moderate emetic activity. However, it is also possible that the nausea and vomiting associated to low-dose cisplatinum and cyclophosphamide-based treatments, is mediated mainly through central mechanisms; whereas that induced by highdose cisplatinum and dacarbazine may be triggered by peripheral as well as by central mechanisms. Thus, serotonin and 5-HT3 receptors play a role both at the periphery as well as in the CNS, and the relative contribution of peripheral and central sites may vary with the type of cytotoxic agent employed, its dose and mechanism of action.
